Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE rAHF-PFM): A Phase 4 Study Comparing Two Prophylactic Regimens in Subjects With Severe or Moderately Severe Hemophilia A

NCT00243386 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT00243386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00243386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE rAHF-PFM): A Phase 4 Study Comparing Two Prophylactic Regimens in Subjects With Severe or Moderately Severe Hemophilia A
Lead sponsor
Baxalta now part of Shire
Phase
Phase 4
Overall status
Completed
Start date
January 4, 2006
Completion date
June 16, 2010
Enrollment
82 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a